A nucleosome switch primes hepatitis B virus infection by Nicholas Prescott et al.
A paper by Nicholas Prescott et al. was published in Cell, titled:
“A nucleosome switch primes hepatitis B virus infection”
Authors: Nicholas Prescott, Viviana Risca, Robert Schwartz, Yael David et al.
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared this article on LinkedIn, commenting:
“Breakthrough in Hepatitis B Research!
Scientists at Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University have uncovered a new way to disrupt HBV infection – using a drug already in clinical trials for cancer!
By studying how HBV DNA wraps around human histones, researchers found that targeting this process with CBL137 could inhibit infection in human liver cells.
This discovery, published in Cell, paves the way for new treatments against one of the deadliest infections worldwide, affecting 250M+ people and causing 1M+ deaths annually.”
More posts featuring Yan Leyfman.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023